

Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief


Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?
- NIH agrees to review hundreds of denied or shelved grant applications
- Paul Engstrom, Fox Chase pioneer of cancer prevention, dies at 89
- MSK’s AML researcher Bayard “Barney” Clarkson, former president of ASCO and AACR, dies at 99










